Skin compositions and methods of use thereof

1. A body corrective formulation for application to skin, comprising:

a) a reactive reinforcing component comprising (i) a reactive constituent comprising at least one organopolysiloxane and at least one hydride functionalized polysiloxane and (ii) a reinforcing constituent;

wherein the organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane, wherein the high viscosity and low viscosity organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:

wherein

R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are each independently C 1-20 alkyl;

p and q are each independently an integer from between 10 and 6000;

R 1b , R 2b , R 3b , R 6b , R 7b and R 8b are C 1-20 alkyl;

R 4b , R 5b , R 9b and R 10b are each independently selected from hydrogen, C 1-20 alkyl, or C 5-10 aryl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;

m and n are each independently an integer from between 10 and 6000; and

wherein said reactive reinforcing component has a viscosity of about 50,000 to about 700,000 cSt or cP at 25° C.,

wherein the high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C. and the low viscosity organopolysiloxane has a viscosity of about 10,000 to about 50,000 cSt or cP at 25° C.; and

b) a cross-linking component that comprises a metal catalyst;

wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a body corrective film is formed on the skin.

2. The formulation of claim 1 , wherein the high viscosity organopolysiloxane has a viscosity of about 150,000 to about 185,000 cSt or cP at 25° C. and the low viscosity organopolysiloxane has a viscosity of about 10,000 to about 15,000 cSt or cP at 25° C.

3. The formulation of claim 1 , wherein said high viscosity organopolysiloxane has a weight percent of vinyl of about 0.05 to about 0.1 or a vinyl equivalent per kilogram of about 0.001 to about 0.05 or a combination of both.

4. The formulation of claim 1 , wherein said low viscosity organopolysiloxane has a weight percent of vinyl of about 0.01 to about 0.5 or a vinyl equivalent per kilogram of about 0.001 to about 0.1 or a combination of both.

5. The formulation of claim 1 , wherein said hydride functionalized polysiloxane has a viscosity of about 2 to about 10,000 cSt or cP at 25° C.

6. The formulation of claim 1 , wherein said hydride functionalized polysiloxane has a viscosity of about 25 to about 500 cSt or cP at 25° C.

7. The formulation of claim 1 , wherein said hydride functionalized polysiloxane has a percent SiH content of about 5 to about 75% or a SiH content of about 0.5 to about 10 mmol/g or a combination of both.

8. The formulation of claim 1 , wherein said hydride functionalized polysiloxane comprises trimethylsiloxy terminated methylhydrosiloxane-dimethylsiloxane copolymers.

9. The formulation of claim 1 , wherein said reactive reinforcing component has a vinyl organopolysiloxane to functional hydride molar ratio of about 1:25 to about 1:70.

10. The formulation of claim 1 , wherein said reinforcing constituent is selected from the group consisting of optionally surface treated mica, zinc oxide, titanium dioxide, aluminum oxide, clay or silica.

11. The formulation of claim 1 , wherein the catalyst comprises about 0.005 to about 0.04% of the cross-linking component.

12. The formulation of claim 1 , wherein the formulation comprises

(i) about 20% to about 60% of the reactive constituent comprising at least one high viscosity vinyl-terminated polydimethylsiloxane and at least one low viscosity vinyl-terminated polydimethylsiloxane and at least one trimethyl-siloxy terminated methylhydrosiloxane-dimethylsiloxane copolymer; and

(ii) about 8% to about 13% silica; and

wherein the cross-linking component comprises a platinum catalyst.

13. A body corrective formulation for application to the skin, comprising:

about 10,000 cSt vinyl-terminated dimethylpolysiloxane;

about 165,000 cps vinyl-terminated dimethylpolysiloxane;

Alkyl-terminated silicon-hydride polysiloxane; and

Platinum-divinyltetramethyldisiloxane complex.

14. A wrinkle corrective formulation for application to the skin, comprising:

a) a reactive reinforcing component, wherein the organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane, wherein the high viscosity and low viscosity organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:

wherein

R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are each independently C 1-20 alkyl;

p and q are each independently an integer from between 10 and 6000;

R 1b , R 2b , R 3b , R 6b , R 7b and R 8b are C 1-20 alkyl;

R 4b , R 5b , R 9b and R 10b are each independently selected from hydrogen, C 1-20 alkyl, or C 5-10 aryl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;

m and n are each independently an integer from between 10 and 6000; and

wherein said reactive reinforcing component has a viscosity of about 50,000 to about 700,000 cSt or cP at 25° C.,

wherein the high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C. and the low viscosity organopolysiloxane has a viscosity of about 10,000 to about 50,000 cSt or cP at 25° C.; and

b) a cross-linking component that comprises a metal catalyst;

wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a wrinkle corrective film is formed on skin, and wherein said film when formed reduces the appearance of wrinkles.

15. A bag reducing formulation for application to the skin, comprising:

a) a reactive reinforcing component, wherein the organopolysiloxane is a combination of at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane, wherein the high viscosity and low viscosity organopolysiloxanes are polymers of formula II and said hydride functionalized polysiloxane is a polymer of formula III:

wherein

R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are each independently C 1-20 alkyl;

p and q are each independently an integer from between 10 and 6000;

R 1b , R 2b , R 3b , R 6b , R 7b and R 8b are C 1-20 alkyl;

R 4b , R 5b , R 9b and R 10b are each independently selected from hydrogen, C 1-20 alkyl, or C 5-10 aryl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen;

m and n are each independently an integer from between 10 and 6000; and

wherein said reactive reinforcing component has a viscosity of about 50,000 to about 700,000 cSt or cP at 25° C.,

wherein the high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C. and the low viscosity organopolysiloxane has a viscosity of about 10,000 to about 50,000 cSt or cP at 25° C.; and

b) a cross-linking component that comprises a metal catalyst; wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a bag reducing film is formed on skin, and wherein said film when formed reduces the appearance of bags under the eyes.

16. The body corrective formulation of claim 13 , comprising:

10,000 cSt vinyl-terminated dimethylpolysiloxane;

165,000 cps vinyl-terminated dimethylpolysiloxane; Alkyl-terminated silicon-hydride polysiloxane; and Platinum-divinyltetramethyldisiloxane complex.

17. The body corrective formulation of claim 1 , wherein the low viscosity organopolysiloxane has a viscosity of about 10,000 cSt or cP at 25° C.

18. The wrinkle corrective formulation of claim 14 , wherein the low viscosity organopolysiloxane has a viscosity of about 10,000 cSt or cP at 25° C.

19. The bag reducing formulation of claim 15 , wherein the low viscosity organopolysiloxane has a viscosity of about 10,000 cSt or cP at 25° C.